Serimmune, Inc.

DUBLIN--( BUSINESS WIRE )--The "Parasitology and Mycology Rapid Tests and POC Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" report has been added to ResearchAndMarkets.com's offering. Parasitology & Mycology Pipeline Report provides comprehensive information about the Parasitology & Mycology pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. This report provides extensive coverage of Parasitology & Mycology under development, offering comprehensive insights into pipeline products, major players, developmental activities, clinical trial data, and recent developments in the segment/industry. The report reviews the details of major pipeline products, including product descriptions, licensing and collaboration details, and other developmental activities related to Parasitology & Mycology. It also lists all the pipeline projects involving major players engaged in the development of Parasitology & Mycology. Coverage of pipeline products is based on various stages of development, ranging from Early Development to Approved/Issued stages, allowing readers to understand the progress of these products in the pipeline. Key clinical trial data related to ongoing trials specific to pipeline products in the Parasitology & Mycology segment is provided, offering valuable insights into the clinical development of these products. Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage Identify and understand important and diverse types of Parasitology & Mycology under development Develop market-entry and market expansion strategies Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline In-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Parasitology & Mycology Overview 3 Products under Development 3.1 Parasitology & Mycology - Pipeline Products by Stage of Development 3.2 Parasitology & Mycology - Pipeline Products by Territory 3.3 Parasitology & Mycology - Pipeline Products by Regulatory Path 3.4 Parasitology & Mycology - Pipeline Products by Estimated Approval Date 4 Parasitology & Mycology - Pipeline Products under Development by Companies 4.1 Parasitology & Mycology Companies - Pipeline Products by Stage of Development 4.2 Parasitology & Mycology - Pipeline Products by Stage of Development 5 Parasitology & Mycology Companies and Product Overview 6 Parasitology & Mycology- Recent Developments 7 Appendix A selection of companies mentioned in this report includes Abacus Diagnostica Ltd Access Bio Inc Acobiom Adaltis Srl All India Institute of Medical Sciences Antigen Discovery Inc Applied BioCode Inc Aptus Biotech SL Attogene Corp Auburn University Axxin Beckman Coulter Inc BioSynesis Inc Biotechnology Assets SA Biotype Innovation GmbH Cascade Biosystems Inc Cepheid Inc Cerebro Biosystems Ceres Nanosciences Inc Ellume Ltd EUROIMMUN US LLC FK-Biotecnologia SA Foundation for Innovative New Diagnostics Fungea AB G Medical Health and Wellness Genetag Technology, Inc Gennova Biopharmaceuticals Ltd Genome Diagnostics Pvt Ltd George Mason University Great Basin Scientific Inc. HealthTell Inc Immunetics Inc InBios International Inc Institute for Development Research Johns Hopkins University L2 Diagnostics LLC London School of Hygiene & Tropical Medicine Luminex Corp Mahidol Oxford Tropical Medicine Research Unit Masaryk University Massachusetts Institute of Technology McGill University Meridian Bioscience Inc Microbiologics Inc MiraVista Diagnostics LLC MND Diagnostic LTD MycoDART Inc Mylab Discovery Solutions Pvt Ltd Nagasaki University Nanosphere Inc (Inactive) NextGen Invitro Diagnostics Pvt Ltd Novacyt SA Ohio State University OpGen Inc OPKO Health Inc Oregon Health & Science University Ortho Clinical Diagnostics Holdings Plc Pai Life Sciences Inc Paramedical Srl Peruvian Cayetano Heredia University Phagolum Ltd. PixCell Medical Technologies Ltd Praxis Pharmaceutical SAU Proplex Technologies Llc Qiagen NV RealSeq Biosciences Inc Roche Diagnostics International Ltd Seegene Inc Serimmune Inc Siemens Healthcare Diagnostics Inc T2 Biosystems Inc Taizhou ZECEN Biotech Co Ltd Techinvention Lifecare Pvt Ltd The Walter and Eliza Hall Institute of Medical Research Transfusion & Transplantation Technologies (Inactive) University of California University of Colorado University of Edinburgh University of Georgia University of Grenoble Alpes University of Oxford University of Tennessee Virginia Commonwealth University Washington University in St Louis Washington University School of Medicine For more information about this report visit https://www.researchandmarkets.com/r/djd3pp About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Company to chair session on new vaccine development on Tuesday, November 14, 2023, at 3:20 p.m. ET --(BUSINESS WIRE)-- WHAT: SerImmune will discuss its Serum Epitope Repertoire Analysis (SERA) platform and how it can be applied in various studies to gain insight into past and present humoral immune responses in individuals and cohorts. The new vaccine development session will be led by Dr. John Shon and will review how SERA allows for the detection of an unlimited number of B cell immune responses in a single assay, enabling comparative immunomics and precision immunology. WHY: Individuals are exposed to a wide variety of environmental, infectious, vaccines and therapeutic agents stimulating humoral immune response. Whether studying longitudinal samples, novel formulations of vaccines or boosters, pre-clinical vs. clinical vaccine responses, or vaccine vs. natural infection, SERA enables comparative, high-throughput, high-resolution analysis of epitopes to enable precision immunology, supporting the next generation of vaccine development. WHO: Serimmune and Vaccine Summit 2023 will bring together experts in the field of vaccine research as well as industry leaders to address current issues facing vaccine development. The “New Vaccine Development” session will be led by Dr. John Shon, Chief Technology Officer, Serimmune. WHEN: “SERA: universal serology enabling high-throughput, antigen agnostic studies of adaptive immune responses” will be held Tuesday, November 14, 2023, at 3:20 p.m. ET / 12:20 p.m. PT. WHERE: Vaccine Summit 2023 at the Sheraton Boston Needham Hotel, Grand Ballroom. To register click here: About Serimmune Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens. The company’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmune’s human immunity map is a growing database that can be interrogated to uncover disease information for the development of multiplex diagnostics, vaccines and therapeutics. The company was founded in 2014 and is backed by investors such as Illumina Ventures, LabCorp, and Merck. For more information visit serimmune.com or follow us on Facebook, Twitter and LinkedIn.

Mount Sinai-Yale Long COVID (MY-LC) study found key differences in the blood of Long COVID patients. GOLETA, Calif.--(BUSINESS WIRE)-- SerImmune, a leader in understanding the antibody repertoire's role in human disease, announced today the publication of a study in Nature in which their proprietary Serum Epitope Repertoire Analysis (SERA) technology platform was one of the methods used to analyze the biological processes associated with the development and persistence of Long COVID symptoms, such as fatigue, brain fog and malaise. The cross-sectional study of 273 individuals, which included multi-dimensional immune phenotyping and unbiased machine learning, determined that there are significant biological differences in the blood of people experiencing Long COVID compared to the control group of those who are not, even after one year. In the article titled, “Distinguishing features of Long COVID identified through immune profiling,” the authors describe how complementary approaches, including Serimmune's SERA platform and enzyme-linked immunosorbent assay (ELISA) were used to examine antiviral reactivity patterns in participants. The SERA platform was also used to analyze non-SARS-CoV-2 antigens. Findings from the study showed that individuals with Long COVID have elevated antibody responses directed against both SARS-CoV-2 and non-SARS-CoV-2 viral antigens, particularly Epstein-Barr virus (EBV) antigens. A recent report from the Centers for Disease Control and Prevention (CDC) found that even though the rate of Long COVID is declining, one in four adults with Long COVID struggle to perform activities-of-daily-living. This impacts their quality of life, ability to work or provide care for others. “The burdens of this disease are great and touch the lives of many of our families and friends,” said Malek Faham, MD, PhD, CEO of Serimmune. “We are driven to improve the way diseases like Long COVID are diagnosed and treated through our state-of-the-art immunology, next generation sequencing, bioinformatics and machine learning. We partner with academic institutions, biopharma, healthcare organizations and government so we can assist them with their immune-related research, product development and healthcare decisions.” SERA is a universal serology platform that utilizes bacterial display peptide library technology and next generation sequencing to broadly pro repertoires and identify the antigens and epitopes associated with many diseases – all in a single assay. About Serimmune Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens. The company’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmune’s human immunity map is a growing database that can be interrogated to uncover disease information for the development of multiplex diagnostics, vaccines and therapeutics. The company was founded in 2014 and is backed by investors such as Illumina Ventures, LabCorp, and Merck. For more information visit serimmune.com or follow us on Facebook, Twitter and LinkedIn.